Loading...
Market
How many patients will be using Synchron's BCI technology with Apple's Vision Pro by December 31, 2024?
2
Resolution / Starting Odds
Less than 50 • 25%
50 to 100 • 25%
101 to 200 • 25%
More than 200 • 25%
Official statistics from Synchron or Apple, or major news outlets
Story
Synchron Integrates BCI with Apple's Vision Pro in Industry First, Enabling ALS Patient Thought Control
Jul 30, 2024, 03:42 PM
Neuralink rival Synchron has successfully integrated its brain-computer interface (BCI) technology with Apple's Vision Pro headset, allowing patients to control the device using their thoughts. This groundbreaking development enables individuals with limited physical mobility, such as those suffering from ALS, to interact with the Vision Pro hands-free. Mark, a 64-year-old man with ALS, demonstrated the technology by using his thoughts to control the cursor on the Vision Pro. This integration marks an industry first and follows Synchron's previous tests with similar technology on the iPad and iPhone. The technology also integrates ChatGPT, enhancing its capabilities.
View original story
Similar markets
Less than 10 • 25%
10 to 50 • 25%
51 to 100 • 25%
More than 100 • 25%
Less than 100 • 25%
100-500 • 25%
501-1000 • 25%
More than 1000 • 25%
Yes • 50%
No • 50%
FDA approval for commercial use • 25%
Integration with another major tech device • 25%
Partnership with a major tech company • 25%
Clinical trials expansion • 25%
0-10 • 25%
11-50 • 25%
51-100 • 25%
More than 100 • 25%
Less than 10 • 25%
10 to 50 • 25%
51 to 100 • 25%
More than 100 • 25%
Less than 100 • 25%
100-499 • 25%
500-999 • 25%
1000 or more • 25%
1-5 patients • 25%
6-10 patients • 25%
11-20 patients • 25%
More than 20 patients • 25%
0-4 • 25%
5-9 • 25%
10-14 • 25%
Less than 5 • 25%
5 to 9 • 25%
10 to 14 • 25%
15 or more • 25%
Communication enhancement for ALS patients • 25%
Cognitive enhancement for general users • 25%
Control of tech devices like Apple Vision Pro • 25%
Medical research and trials • 25%
0-4 • 25%
5-9 • 25%
10-14 • 25%
15 or more • 25%